Brian H. Dovey is Director at Orexigen Therapeutics, Inc. (OREX). They have made 49 open-market trades across 16 companies since 2006, most recently 2018-06-29.
CIK 0001207786
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
23 open-market purchases totalling $102.1M since 2006, against 26 sales. Across 5 scored buys the stock is down 2.6% at ninety days, and 2.9 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 0% |
| Avg Move | -28.1% | -2.6% | -2.6% |
| Alpha | -22.3% | -2.9% | -2.9% |
| Scored | 5 | 5 | 5 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 33% | 17% |
| Avg Move | +2.0% | +14.8% | +133.1% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CLCD | SELL | 2016-08-03 | 2016-08-03 | $8.15 | $661K | +11.5% | +35.6% | +303.9% |
| CLCD | SELL | 2016-08-02 | 2016-08-03 | $8.71 | $172K | +11.5% | +35.6% | +303.9% |
| CLCD | SELL | 2016-08-01 | 2016-08-03 | $8.45 | $2K | +11.5% | +35.6% | +303.9% |
| CLCD | SELL | 2016-08-01 | 2016-08-03 | $8.45 | $1.3M | +11.5% | +35.6% | +303.9% |
| CLCD | SELL | 2016-08-01 | 2016-08-03 | $8.82 | $461K | +11.5% | +35.6% | +303.9% |
| CLCD | SELL | 2016-04-28 | 2016-05-02 | $6.96 | $2K | -10.1% | +4.5% | +26.5% |
| EVOK | SELL | 2016-04-19 | 2016-04-21 | $5.35 | $4K | -2.6% | +2.8% | -60.4% |
| EVOK | SELL | 2016-04-08 | 2016-04-08 | $5.35 | $78K | +1.2% | -2.3% | +37.4% |
| EVOK | SELL | 2016-04-07 | 2016-04-08 | $5.26 | $146K | +1.2% | -2.3% | +37.4% |
| EVOK | SELL | 2016-04-06 | 2016-04-08 | $5.28 | $269K | +1.2% | -2.3% | +37.4% |
| RGDO | BUY | 2013-08-27 | 2013-08-28 | $4.00 | $3.0M | N/A | N/A | N/A |
| OCRX | BUY | 2013-07-15 | 2013-07-31 | $6.03 | $8.0M | N/A | N/A | N/A |
| ESPR | BUY | 2013-07-01 | 2013-07-02 | $14.00 | $4.0M | -35.3% | -0.8% | -0.8% |
| ALIM | SELL · 10b5-1 | 2013-06-18 | 2013-06-20 | $5.39 | $298K | -20.2% | +0.0% | +0.0% |
| ALIM | SELL · 10b5-1 | 2013-06-11 | 2013-06-13 | $5.00 | $27K | -20.2% | +0.0% | +0.0% |
| CADX | SELL · 10b5-1 | 2013-04-08 | 2013-04-10 | $6.62 | $514K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-21 | 2013-03-22 | $5.35 | $23K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-21 | 2013-03-22 | $5.35 | $72K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-21 | 2013-03-22 | $5.49 | $5K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-19 | 2013-03-21 | $5.20 | $2K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-19 | 2013-03-21 | $5.20 | $1K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-15 | 2013-03-19 | $5.23 | $2K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-03-13 | 2013-03-15 | $5.38 | $212K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-01-24 | 2013-01-28 | $5.43 | $272K | N/A | N/A | N/A |
| CADX | SELL · 10b5-1 | 2013-01-17 | 2013-01-22 | $5.25 | $6K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| SNDX | 1,743,854 | $22.5M |
| ALIM | 3,920,630 | $21.7M |
| ESPR | 2,066,935 | $6.6M |
| ZGNX | 169,251 | $4.5M |
| CLVS | 2,990,937 | $243K |
| EVOK | 16,290 | $179K |
| VNDA | 21,068 | $85K |
| ALDX | 9,208 | $6K |
| AKAO | 33,890 | $4K |
| OTIC | 32,745 | $3K |
| RGDO | 2,571,117 | — |
| IOMI | 1,699,794 | — |
| SENO | 1,344,783 | — |
| SOMX | 1,714,789 | — |
| CADX | 7,384,819 | — |
| VOLC | 14,782 | — |
| RVA | 15,500 | — |
| NOVC | 3,054,396 | — |
| NSTR | 37,586 | — |
| DRTX | 3,006,132 | — |
| OCRX | 988,285 | — |
| OREX | 7,580,065 | — |
| Total | $544.2M |
Shares reported on the most recent Form 4, priced at the 2018-07-03 close. 12 holdings could not be priced and are excluded from the total.
| Scored | 12 | 12 | 12 |